Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories

Leukemia

Volumn 22, Issue 1, 2008, Pages 96-102

  Muller M C ^a   Erben, P ^a   Saglio, G ^b   Gottardi, E ^b   Nyvold, C G ^c   Schenk, T ^a   Ernst, T ^a   Lauber, S ^a   Kruth, J ^a   Hehlmann, R ^a   Hochhaus, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA GLUCURONIDASE; MESSENGER RNA;

AGED; ANALYTIC METHOD; ARTICLE; CALIBRATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; HUMAN; HUMAN CELL; LABORATORY; LEUKOCYTE; MALE; PLASMID; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STANDARDIZATION;

EID: 38349081290     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404983     Document Type: Article

References (15)

1. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
2. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J et al Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: Low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study droup. Blood 2000; 95: 62-66.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular resppnses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423-1432.
4. Mülller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia 2003; 17: 2392-2400.
5. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European leukemiaNet. Blood 2006; 108: 1809-1820.
6. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Mobitoring CML ptients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28-37.
7. Burmeister T, Maurer J, Aivado M, Elmaagacli AH, Grunebach F, Held KR et al. Quality assurance in RT-PCR-based BCR/ABL diagnostics - results of an interlaboratory test and a standardization approach. Leukemia 2000; 14: 1850-1856.
8. Müller MC, Hördt T, Paschka P, Merx K, La Rosee P, Hehlmann R et al. Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia. Acta Haematol 2004; 112: 30-33.
9. Weisser A, La Rosee P, Burmeister T, Raff T, Kneba M, Hehlmann R et al. Sensitivity, quality and comparability of BCR-ABL quantification by RT-PCR: Results of an interlaboratory analysis. [Abstract]. Blood 2001; 98 (Suppl 1): 320a.
10. Müller MC, Saglio G, Lin F, Pfeifer H, Press RD, Tubbs RR et al An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR. Haematologica 2007; 92: 970-973.
11. Müller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R et al Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002; 16: 2395-2399.
12. Gabert J, Beillard E, van der Velden V, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukaemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
13. Emig M, Saussele S, Wittor H, Weisser A, Reiter A, Willer A et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR. Leukemia 1999; 13: 1825-1832.
14. Beillard E, Pallisgaard N, van der Velden V, Bi W, Dee R, van der SE et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe Against Cancer program. Leukemia 2003; 17: 2474-2486.
15. Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J et al Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia 2006; 20: 1925-1930.